SynChem boosts Formosa’s presence
Formosa Laboratories, a Taiwan-based API supplier and CDMO, has completed the acquisition of SynChem, a contract research laboratory located in suburban Chicago. SynChem will now operate as SynChem-Formosa, with Dr W. Paul Mar continuing as CEO. Terms were not disclosed.
Dr Cheng, chairman and president of Formosa, particularly noted SynChem's track record in areas such as ADC payloads and linkers. Added to Formosa’s capabilities in scale-up, commercial GMP production, bio-conjugation and injectable fill-finish operations, he said, “we are now poised to offer comprehensive, fully GMP-compliant CDMO services to our clients across the US and internationally.”
RELATED ARTICLES
French-based CDMO EuroAPI has reached an agreement with Sanofi to finance the implementation of its Focus-27 restructuring programme through a €200 million perpetual subordinated hybrid bond. Sanofi, from which EuroAPI was originally spun out, remains its main shareholder and customer.
Following an expansion and qualification phase, the consortium formed by Wacker Chemie and CordenPharma in Germany officially entered ‘pandemic readiness’ for the production of mRNA-based vaccines as of 1 June.
Veranova has initiated a “significant” expansion of its ADC and highly potent compound development and manufacturing capabilities at Devens, Massachusetts, at a cost of about $30 million.
Swiss CDMO Dottikon Exclusive Synthesis (ES) is in the process of investing around CHF 700 million (€730 million) in new production and drying plants for APIs at its production site in Dottikon.
Drug development services supplier CatSci has acquired its UK compatriot Reach Separations. No financial details were disclosed but the company said that this deal was supported by Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments.
The European Commission has informed India’s Alchem International and its Hong Kong subsidiary of its preliminary view “that they have breached EU antitrust rules by participating in a long-lasting cartel concerning an important pharmaceutical product”.
